Atara Biotherapeutics completes enrollment in PINTA 745 phase 2 clinical trial
The company expects to report preliminary top-line data by the end of the fourth quarter of 2015. PINTA 745 is a peptibody that binds myostatin and inhibits its
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
The clinical trial, dubbed EVEREST, will evaluate the antiviral activity, safety and pharmacokinetics of a combination regimen of Danoprevir (ASC08), a direct-acting antiviral agent and NS3/4A inhibitor, and
The twice-a-day product can be used in adult males for conditions related with a deficiency or absence of endogenous testosterone (hypogonadism). The company’s oral androgen replacement (SOAR) pivotal
The agreement formalizes a relationship between QB3@953 and GSK’s Discovery Partnerships with Academia (DPAc) team and creates a new channel for DPAc to identify early-stage opportunities. The agreement
The Israeli patent application No. 207420 is entitled "Methods and Compositions for Treating Inflammatory Bowel Disease". Once granted, the patent is expected to be valid through at least